Physician profile
Albert Liao
NPI 1801390216
$3,682.15
in general payments reported to CMS, 2019-2025
10 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,364 · 2023: $1,355 · 2024: $682 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223 · Travel and Lodging: $95.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.71 |
| Travel and Lodging | $95.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,186.45 | 2022-2023 | Dailies Total1, Precision 1, Total30 |
| Abbvie INC. | $1,054.68 | 2022-2025 | |
| Genentech USA, INC. | $409.74 | 2023-2024 | Vabysmo |
| Dutch Ophthalmic, USA | $354.28 | 2023 | Tissueblue, Eva, Combined Machine |
| Regeneron Healthcare Solutions, INC. | $229.94 | 2023-2025 | Eylea Hd, Eylea |
| Genentech, INC. | $147.78 | 2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $120.85 | 2024 | Syfovre |
| Alimera Sciences, INC. | $119.00 | 2023 | Iluvien |
| Tarsus Pharmaceuticals, INC. | $33.59 | 2025 | Xdemvy |
| Dompe US, INC. | $25.84 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Liao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.